This profile has not been claimed and data may not be accurate.
79th percentile
Co-founder of Ginkgo Bioworks, synthetic biology platform taken public via SPAC in 2021
Credibility
Operator · 74th percentile
- Current founder of Ginkgo Bioworks, a role he has held since 2008.
- Ginkgo Bioworks is a Y Combinator S14 alum.
- Ginkgo Bioworks was co-founded by Austin Che alongside Jason Kelly, Reshma Shetty, and Barry Canton.
Relationship Matrix
Most Like You
Most Complimentary
Founder score
- 98%Probability of being accurate (98%)Current founder of Ginkgo Bioworks, a role he has held since 2008.
- 97%Probability of being accurate (97%)Ginkgo Bioworks was co-founded by Austin Che alongside Jason Kelly, Reshma Shetty, and Barry Canton.
- 95%Probability of being accurate (95%)ginkgo.bio ranks #75,028 on the Majestic Million (global domain prominence).
- 95%Probability of being accurate (95%)Ginkgo Bioworks is a Y Combinator S14 alum.
- 90%Probability of being accurate (90%)Ginkgo Bioworks went public via a SPAC merger in 2021, representing an IPO-equivalent exit for its founders.
- 80%Probability of being accurate (80%)GitHub account @austinche identified and confirmed as Austin Che's account.
- 80%Probability of being accurate (80%)GitHub account @austinche has been active for over 13 years (created 2012).
- 75%Probability of being accurate (75%)Identified Hacker News account @ache confirmed via keybase proof in the HN bio.
- 60%Probability of being accurate (60%)Identified as a researcher on OpenAlex with an h-index of 4 and 58 citations across 17 works.
- 55%Probability of being accurate (55%)Ginkgo Bioworks is a publicly traded company (IPO 2021) and continues to operate as a going concern.
What you likely need
You'd get the most out of Festival events that put you in rooms with late-stage founders and public-market investors who can absorb your SPAC and synthetic biology expertise — and turn it into deal flow, co-investment, and advisory relationships. Dinners and roundtables that surface your YC S14-to-IPO arc and your Ginkgo platform credibility will do more for your personal brand than any solo publishing effort. The highest-leverage gatherings are ones where your operator depth at Ginkgo and your early board work at Aether Biomachines position you as the rare technical founder who has also navigated the full company-building lifecycle.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- positioningA dinner for founders who took companies public via SPAC — including Ginkgo-era peers — to swap war stories and surface the honest SPAC narrative Austin is best positioned to publish
- introsA YC S14 alumni roundtable for founders who have since scaled or gone public, so Austin can re-engage the cohort as a mentor and anchor a speaker slot around the S14-to-IPO journey
- fundraisingA dinner for biotech-focused angel investors and venture partners — including 3CC Management and Aether Biomachines co-investors — to formalize co-investment relationships around Austin's early-stage synthetic biology deal flow
- positioningAn HN-community meetup for technical founders and researchers building autonomous lab and synthetic biology tooling, anchored by Austin posting a Show HN or Ask HN thread from Ginkgo's platform work ahead of the event
- introsA YC mentor and guest-speaker happy hour where Austin can re-engage current YC batches as the rare S14 alum who navigated a full SPAC IPO, generating warm inbound from founders and YC partners alike
- tacticalA dinner for synthetic biology and lab-automation engineers who contribute to open-source tooling, where Austin can workshop which Ginkgo platform datasets or internal tools are most worth open-sourcing under his personal GitHub org
- positioningA roundtable for founders running dual operating roles or co-CEO structures — anchored around Austin's current Altar SAS commitment — to sharpen how he publicly communicates bandwidth and current focus to inbound partners and investors
- introsA dinner for operator-angels systematically building early-stage biotech portfolios, where Austin can leverage his Aether Biomachines board seat and Ginkgo ecosystem relationships to source and vet the next wave of synthetic biology investments